Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.41 |
| ▸ | TOP2A | P11388 | 8/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044998 | 0.95 | HCAR3 (0.43) | HCAR3TOP2ATOP2BALDH1A1KEAP1 | |
| SCHEMBL6044966 | 0.79 | HCAR3 (0.48) | HCAR3TOP2ATOP2BNOTUMALDH1A1 | |
| SCHEMBL6044720 | 0.76 | HCAR3 (0.51) | HCAR3ALDH1A1LMNA | |
| SCHEMBL6044841 | 0.75 | HCAR3 (0.38) | HCAR3 | |
| SCHEMBL6043830 | 0.74 | HCAR3 (0.50) | HCAR3ALDH1A1LMNA | |
| SCHEMBL6044172 | 0.73 | HCAR3 (0.58) | HCAR3ALDH1A1LMNA | |
| SCHEMBL6043996 | 0.72 | HCAR3 (0.50) | HCAR3ALDH1A1CYP11B2LMNA | |
| SCHEMBL6044080 | 0.71 | KEAP1 (0.33) | HCAR3KEAP1NFE2L2 | |
| SCHEMBL6043601 | 0.71 | KDM4C (0.34) | KEAP1NFE2L2 | |
| SCHEMBL6044728 | 0.71 | HCAR3 (0.53) | HCAR3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885TOP2A 2407/4885TOP2B 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.